Qiagen N.V. (NASDAQ:QGEN) - Equities researchers at Jefferies Group reduced their Q3 2017 EPS estimates for shares of Qiagen N.V. in a research note issued on Monday. Jefferies Group analyst P. Welford now forecasts that the company will earn $0.31 per share for the quarter, down from their prior forecast of $0.32. Jefferies Group has a “Hold” rating and a $28.00 price target on the stock. Jefferies Group also issued estimates for Qiagen N.V.’s FY2017 earnings at $1.18 EPS and FY2018 earnings at $1.38 EPS.
Qiagen N.V. (NASDAQ:QGEN) last issued its quarterly earnings results on Thursday, July 27th. The company reported $0.30 earnings per share for the quarter, beating the consensus estimate of $0.28 by $0.02. The company had revenue of $349 million during the quarter, compared to analysts’ expectations of $353.09 million. Qiagen N.V. had a return on equity of 10.98% and a net margin of 5.44%. The business’s quarterly revenue was up 4.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.24 earnings per share. TRADEMARK VIOLATION NOTICE: This piece of content was posted by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this piece of content on another website, it was illegally copied and republished in violation of international copyright legislation. The correct version of this piece of content can be accessed at https://stocknewstimes.com/2017/08/01/q3-2017-eps-estimates-for-qiagen-n-v-qgen-cut-by-analyst.html.
A number of other research firms have also weighed in on QGEN. TheStreet lowered Qiagen N.V. from a “b-” rating to a “c” rating in a research note on Monday, April 24th. Commerzbank Ag reissued a “buy” rating on shares of Qiagen N.V. in a research note on Monday, May 15th. BidaskClub raised Qiagen N.V. from a “hold” rating to a “buy” rating in a research note on Wednesday, July 19th. Wells Fargo & Company reissued a “market perform” rating and issued a $31.00 target price (up previously from $28.00) on shares of Qiagen N.V. in a research note on Thursday, July 13th. Finally, Barclays PLC reissued a “buy” rating and issued a $33.00 target price on shares of Qiagen N.V. in a research note on Friday, May 5th. Seven research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $32.28.
Shares of Qiagen N.V. (NASDAQ QGEN) opened at 32.84 on Tuesday. The firm has a market cap of $7.50 billion, a PE ratio of 100.43 and a beta of 1.15. Qiagen N.V. has a 52 week low of $24.86 and a 52 week high of $35.26. The stock has a 50 day moving average price of $34.00 and a 200 day moving average price of $31.00.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. FNY Managed Accounts LLC purchased a new position in Qiagen N.V. during the first quarter worth $103,000. Oppenheimer Asset Management Inc. purchased a new position in Qiagen N.V. during the first quarter worth $114,000. Quadrant Capital Group LLC increased its position in Qiagen N.V. by 403.4% in the first quarter. Quadrant Capital Group LLC now owns 5,517 shares of the company’s stock worth $154,000 after buying an additional 4,421 shares during the period. Rehmann Capital Advisory Group purchased a new position in Qiagen N.V. during the first quarter worth $207,000. Finally, Prudential Financial Inc. purchased a new position in Qiagen N.V. during the first quarter worth $207,000. Hedge funds and other institutional investors own 60.45% of the company’s stock.
About Qiagen N.V.
QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.
Receive News & Ratings for Qiagen N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen N.V. and related companies with MarketBeat.com's FREE daily email newsletter.
